HIHenrik Iversen

Henrik Iversen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Henrik Iversen has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Locally recurrent rectal cancer: oncological outcomes with different treatment strategies in two tertiary referral units

    by Stefi Nordkamp, Eva L. K. Voogt, Desley M. G. I. van Zoggel, Anna Martling, Torbjörn Holm, Gabriella Jansson Palmer, Chikako Suzuki, Joost Nederend, Miranda Kusters, Jacobus W. A. Burger, et al.

    Background: The optimal treatment for patients with locally recurrent rectal cancer (LRRC) is controversial. The aim of this study was to investigate different treatment strategies in two leading tertiary referral hospitals in Europe. Methods: All patients who underwent curative surgery for LRRC between January 2003 and December 2017 in Catharina Hospital, Eindhoven, the Netherlands (CHE), or Karolinska University Hospital, Stockholm, Sweden (KAR), were studied retrospectively. Available MRIs were reviewed to obtain a uniform staging for optimal comparison of both cohorts. The main outcomes studied were overall survival (OS), local re-recurrence-free survival (LRFS), and metastasis-free survival (MFS). Results: In total, 377 patients were included, of whom 126 and 251 patients came from KAR and CHE respectively. At 5 years, the LRFS rate was 62.3 per cent in KAR versus 42.3 per cent in CHE (P = 0.017), whereas OS and MFS were similar. A clear surgical resection margin (R0) was the strongest prognostic factor for survival, with a hazard ratio of 2.23 (95 per cent c.i. 1.74 to 2.86; P < 0.001), 3.96 (2.87 to 5.47; P < 0.001), and 2.00 (1.48 to 2.69; P < 0.001) for OS, LRFS, and MFS respectively. KAR performed more extensive operations, resulting in more R0 resections than in CHE (76.2 versus 61.4 per cent; P = 0.004), whereas CHE relied more on neoadjuvant treatment and intraoperative radiotherapy, to reduce the morbidity of multivisceral resections (P < 0.001). Conclusion: In radiotherapy-naive patients, neoadjuvant full-course chemoradiation confers the best oncological outcome. However, neoadjuvant therapy does not diminish the need for extended radical surgery to increase R0 resection rates.


  • Magnetic resonance imaging as a predictor of surgical outcome in patients with local pelvic recurrence of colorectal cancer

    by Karin Westberg, Barwar Othman, Chikako Suzuki, Lennart Blomqvist, Anna Martling, Henrik Iversen


  • Top Cited Papers
    Open Access

    Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy

    by Atsushi Ogura, Tsuyoshi Konishi, Geerard L. Beets, Chris Cunningham, Julio Garcia-Aguilar, Henrik Iversen, Shigeo Toda, In Kyu Lee, Hong Xiang Lee, Keisuke Uehara, et al.

    Local recurrence rates in rectal cancer have reduced dramatically since the introduction of the total mesorectal excision (TME) technique.1 These rates have been lowered further with the use of neoadjuvant chemoradiotherapy or radiotherapy ([C]RT) regimens in appropriate cases, decreasing overall rates of 5-year local recurrence to 5% to 10%.2-4 Western surgeons have always relied on (C)RT to sterilize the lateral compartment, containing internal iliac and obturator lymph nodes, and to alleviate fears of operative morbidity and nerve function disorders associated with a lateral lymph node dissection (LLND), which is mainly performed in the East.5 Furthermore, most Western clinicians consider lateral nodal disease to represent metastatic disease not amendable to cure.5,6


  • Top Cited Papers

    Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer

    by Atsushi Ogura, Tsuyoshi Konishi, Chris Cunningham, Julio Garcia-Aguilar, Henrik Iversen, Shigeo Toda, In Kyu Lee, Hong Xiang Lee, Keisuke Uehara, Peter Lee, et al.

    Purpose: Improvements in magnetic resonance imaging (MRI), total mesorectal excision (TME) surgery, and the use of (chemo)radiotherapy ([C]RT) have improved local control of rectal cancer; however, we have been unable to eradicate local recurrence (LR). Even in the face of TME and negative resection margins (R0), a significant proportion of patients with enlarged lateral lymph nodes (LLNs) suffer from lateral LR (LLR). Japanese studies suggest that the addition of an LLN dissection (LLND) could reduce LLR. This multicenter pooled analysis aims to ascertain whether LLNs actually pose a problem and whether LLND results in fewer LLRs. Patients and Methods: Data from 1,216 consecutive patients with cT3/T4 rectal cancers up to 8 cm from the anal verge who underwent surgery in a 5-year period were collected. LLND was performed in 142 patients (12%). MRIs were re-evaluated with a standardized protocol to assess LLN features. Results: On pretreatment MRI, 703 patients (58%) had visible LLN, and 192 (16%) had a short axis of at least 7 mm. One hundred eight patients developed LR (5-year LR rate, 10.0%), of which 59 (54%) were LLRs (5-year LLR rate, 5.5%). After multivariable analyses, LLNs with a short axis of at least 7 mm resulted in a significantly higher risk of LLR (hazard ratio, 2.060; P = .045) compared with LLNs of less than 7 mm. In patients with LLNs at least 7 mm, (C)RT plus TME plus LLND resulted in a 5-year LLR of 5.7%, which was significantly lower than that in patients who underwent (C)RT plus TME (5-year LLR, 19.5%; P = .042). Conclusion: LLR is still a significant problem after (C)RT plus TME in LLNs with a short axis at least 7 mm on pretreatment MRI. The addition of LLND results in a significantly lower LLR rate.


  • Pelvic local recurrence from colorectal cancer: surgical challenge with changing preconditions

    by Henrik Iversen, Anna Martling, Hemming Johansson, P. J. Nilsson, Torbjörn Holm

    Aim: Although the rate of local recurrence (LR) after colorectal cancer surgery has decreased, it still poses major surgical and oncological challenges. The aims of this study, based on an audit from a tertiary referral centre, was to evaluate determinants associated with outcomes after surgery for pelvic LR and how these have changed over time.Method: Retrospective analysis of all resections for pelvic LR of colorectal cancer performed at the Karolinska University Hospital from January 2003 until August 2009 (period 1) and from September 2009 until November 2013 (period 2) .Results: Ninety‐five patients with pelvic LR were operated on with a curative intent. An R0 resection was achieved in 77% and an R1 resection in 23%. Lateral compartments were invaded in 48% and this proportion increased in resections performed in period 2 (37% vs 60%, P = 0.05). R1 resections were associated with a higher risk of local re‐recurrence than R0 resections (64% vs 16%; OR = 8.90, 95% CI: 2.71–29.78). Lateral recurrences were associated with a lower R0‐resection rate than nonlateral recurrences (63% vs 90%; OR = 0.20, 95% CI: 0.05–0.64) and a higher risk of treatment failure in terms of local re‐recurrence or distant metastases, or death, as first event (hazard ratio [HR] = 1.75, 95% CI: 1.06–2.75). However, in a multivariate analysis only R1 resections remained a significant prognostic factor for treatment failure (HR = 2.37, 95% CI: 1.32–4.27).Conclusion: The proportion of lateral pelvic recurrences has increased over time. In comparison with non‐lateral LRs, lateral LRs are more difficult to resect radically and are associated with worse overall and disease‐free survival. However, with radical surgery many patients with pelvic locally recurrent colorectal cancer may be offered curative treatment.


  • Open Access

    Changes in Clinical Practice Reduce the Rate of Anastomotic Leakage After Colorectal Resections

    by Henrik Iversen, Madelene Ahlberg, Marja Lindqvist, Christian Buchli

    Background: Anastomotic leakage is a serious clinical problem after colorectal resections and is associated with a significantly increased length of stay, morbidity and mortality. The aim of the present study was to evaluate the effect of changes in clinical practice on anastomotic leakage rate after colorectal resections.Methods: Retrospective cohort study based on prospectively collected data. All 894 patients with primary anastomosis after colorectal resection at a tertiary referral center between 2006 and 2013 were analyzed. Changes in clinical practice aiming at reducing the rate of anastomotic leakages were introduced in January 2010 and were characterized by exclusion of perioperative nonsteroidal anti‐inflammatory drugs, introduction of intra‐operative goal‐directed fluid therapy and avoidance of primary anastomoses in emergency resections. The study population was divided into two groups, one treated before and one after the introduction of changes in clinical practice. Groups were compared regarding patient characteristics and incidence of anastomotic leakage.Results: The cumulative incidence of anastomotic leakage after colorectal resections decreased from 10.0% (41 of 409) to 4.5% (22 of 485) after changing clinical practice, relative risk 0.45 (95% CI 0.27–0.75,p= 0.002). The adjusted odds ratio was 0.45 (0.26–0.78,p= 0.004). A separate analysis showed a decrease after colon resections from 9.1% (23 of 252) to 4.5% (14 of 310), relative risk 0.49 (0.26–0.94,p= 0.039), and from 11.5% (18 of 157) to 4.6% (8 of 175) after rectal resections, relative risk 0.40 (0.18–0.89,p= 0.024).Conclusion: Implementing a structured change of clinical practice can significantly reduce the anastomotic leakage rate after colorectal resections.Trial registration: Clinical trial registration number: ACTRN12617001497392.


  • Open Access

    Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer

    by D Pettersson, E Lörinc, T Holm, H Iversen, B Cedermark, B Glimelius, A Martling

    Background: The Stockholm III Trial randomized patients with primary operable rectal cancers to either short-course radiotherapy (RT) with immediate surgery (SRT), short-course RT with surgery delayed 4–8 weeks (SRT-delay) or long-course RT with surgery delayed 4–8 weeks. This preplanned interim analysis examined the pathological outcome of delaying surgery. Methods: Patients randomized to the SRT and SRT-delay arms in the Stockholm III Trial between October 1998 and November 2010 were included, and data were collected in a prospective register. Additional data regarding tumour regression grade, according to Dworak, and circumferential margin were obtained by reassessment of histopathological slides. Results: A total of 462 of 545 randomized patients had specimens available for reassessment. Patients randomized to SRT-delay had earlier ypT categories, and a higher rate of pathological complete responses (11·8 versus 1·7 per cent; P = 0·001) and Dworak grade 4 tumour regression (10·1 versus 1·7 per cent; P < 0·001) than patients randomized to SRT without delay. Positive circumferential resection margins were uncommon (6·3 per cent) and rates did not differ between the two treatment arms. Conclusion: Short-course RT induces tumour downstaging if surgery is performed after an interval of 4–8 weeks.


  • Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial

    by D. Pettersson, B. Glimelius, H. Iversen, H. Johansson, T. Holm, A. Martling

    Background Radiotherapy (RT) in rectal cancer increases postoperative morbidity. A suggested reason is RT‐induced bone marrow depression resulting in impaired leucocyte counts. The ongoing Stockholm III Trial randomizes patients with operable rectal cancers to short‐course RT with immediate surgery (SRT), short‐course RT with surgery delayed for 4–8 weeks (SRT‐delay) and long‐course RT with surgery delayed for 4–8 weeks (LRT‐delay). This study examined differences between the randomization arms regarding leucocyte response and postoperative complications. Methods Patients randomized in the Stockholm III Trial between October 1998 and November 2010 were included. Data were collected in a prospective register. Additional data were obtained by retrospective review of clinical records. Results Of 657 randomized patients, 585 had data on leucocytes. The SRT arm had the highest proportion of postoperative complications (SRT, 52·5 per cent; SRT‐delay, 39·4 per cent; LRT‐delay, 41 per cent; P = 0·010). There was no association between low preoperative leucocyte count and postoperative complications (P = 0·238). Irrespective of randomization arm, patients with an impaired postoperative to preoperative leucocyte ratio had the highest rate of complications (low ratio, 56·6 per cent; intermediate ratio, 46·9 per cent; high ratio, 36·3 per cent; P = 0·010). The SRT arm had the highest proportion of low ratios (SRT, 48·9 per cent; SRT‐delay, 22·8 per cent; LRT‐delay, 22 per cent; P < 0·001). Conclusion An impaired postoperative leucocyte response is associated with postoperative complications. The highest risk is with immediate surgery following short‐course radiotherapy. Registration number: NCT 00904813 ( http://www.clinicaltrials.gov).


  • Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer

    by D. Pettersson, T. Holm, H. Iversen, L. Blomqvist, B. Glimelius, A. Martling

    Background: Short‐course radiotherapy (SRT) with immediate surgery and long‐course chemoradiotherapy (CRT) are currently the standard preoperative treatment options for rectal cancer. SRT with surgery delayed for 4–8 weeks (SRT‐delay) is an option described for patients with locally advanced tumours who are not fit for CRT. This study examined early toxicity, response to radiotherapy (RT) and short‐term outcomes of SRT‐delay. Methods: Patients in the Stockholm region diagnosed with rectal cancer between January 2002 and December 2008, who received SRT (25 Gy over 5–7 days) and had surgery with resection of the primary tumour more than 4 weeks after the start of RT, were identified from a prospective register. Additional data were obtained by retrospective review of clinical records. Results: A total of 112 patients had SRT and delayed surgery. The reasons given for SRT included primary unresectable disease and co‐morbidities. Severe RT‐induced toxicity was noted in six patients (5·4 per cent). Signs of tumour regression were seen on magnetic resonance imaging in 74 per cent of patients reassessed after RT. Pathological stage (44·9 versus 60·7 per cent stage 0–II; P < 0·001), tumour category (11·9 versus 29·4 per cent T0–T2; P < 0·001) and node category (45·8 versus 63·6 per cent N0; P = 0·014) were significantly lower than those at initial assessment. Nine patients (8·0 per cent) had a complete pathological response. Conclusion: The SRT‐delay schedule was a feasible alternative with low toxicity. The study indicated a downstaging effect of SRT if surgery was delayed. Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.


  • Nitric oxide‐dependent relaxation induced by M1 muscarinic receptor activation in the rat small intestine

    by C Olgart, H H Iversen

    The aim of the present study was to investigate whether muscarinic M1 receptor activation induces intestinal relaxation via nerve‐dependent nitric oxide formation. Mechanical activity in longitudinal segments of rat jejunum was recorded isotonically in organ baths. The muscarinic M1 receptor agonist 4‐[[[(3‐Chlorophenyl)amino]carbonyl]oxy]‐N,N,N,‐trimethyl‐2‐butyn‐1‐amonium chloride (McN‐A‐343, 10−7–10−4 M) induced a concentration‐dependent relaxation of rat jejunum. Relaxations induced by McN‐A‐343 (10−5 M) were inhibited by the M1 receptor antagonist telenzepine (10−8 M), and enhanced by the M3 receptor antagonist para‐fluoro‐hexahydrosiladifenidol (p‐F‐HHSiD; 3×10−7 M). The inhibitory responses induced by McN‐A‐343 were abolished by the nitric oxide synthase inhibitors Nω‐nitro‐L‐arginine (L‐NOARG; 10−4 M) and Nω‐monomethyl‐L‐arginine (L‐NMMA; 3×10−5 M), the guanylyl cyclase inhibitor 1H‐[1,2,4]oxadiazolo[4,3,‐a]quinoxalin‐1‐one (ODQ; 10−5 M), and by tetrodotoxin (TTX; 3×10−7 M). Guanethidine or hexamethonium did not affect inhibitory responses induced by McN‐A‐343. In conclusion, McN‐A‐343 induces nerve‐dependent, nitrergic relaxations in rat jejunum, via activation of muscarinic M1 receptors. Hence, selective muscarinic M1 receptor agonists or antagonists might offer possibilities for pharmacological manipulation of the NO system. British Journal of Pharmacology (1999) 127, 309–313; doi:10.1038/sj.bjp.0702529